Distinguished in Olfactory Neuroblastoma

Dr. Robert L. Foote

Radiation Oncology | Radiology
200 1st St Sw, 
Rochester, MN 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Olfactory Neuroblastoma
200 1st St Sw, 
Rochester, MN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robert Foote is a Radiation Oncologist and a Radiologist in Rochester, Minnesota. Dr. Foote is rated as a Distinguished provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Olfactory Neuroblastoma, Adenoid Cystic Carcinoma, Laryngeal Cancer, Gamma Knife Radiosurgery, and Cardiac Ablation.

His clinical research consists of co-authoring 159 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 8 articles in the study of Olfactory Neuroblastoma.

Specialties
Radiation Oncology
Radiology
Licenses
Diagnostic Radiology in MN
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

200 1st St Sw, Rochester, MN 55905

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
Phase III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck
Phase III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck
Enrollment Status: Active_not_recruiting
Publish Date: August 08, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 3
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2025
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
A Phase II Randomized Study of Proton Versus Photon Beam Radiotherapy in the Treatment of Unilateral Head and Neck Cancer
A Phase II Randomized Study of Proton Versus Photon Beam Radiotherapy in the Treatment of Unilateral Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 06, 2025
Intervention Type: Radiation
Study Phase: Phase 2
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Prospective Observational Study of Proton Stereotactic Body Radiation Therapy and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer
A Prospective Observational Study of Proton Stereotactic Body Radiation Therapy and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer
Enrollment Status: Terminated
Publish Date: November 14, 2024
Intervention Type: Radiation, Drug
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2024
Intervention Type: Other, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
View 6 Less Clinical Trials

159 Total Publications

Causal Machine Learning Analysis of Empirical Relative Biological Effectiveness (RBE) for Mandible Osteoradionecrosis in Head and Neck Cancer Radiotherapy.
Causal Machine Learning Analysis of Empirical Relative Biological Effectiveness (RBE) for Mandible Osteoradionecrosis in Head and Neck Cancer Radiotherapy.
Journal: ArXiv
Published: October 03, 2025
Similar Doctors
Advanced in Olfactory Neuroblastoma
Dr. Daniel J. Ma
Radiation Oncology
Advanced in Olfactory Neuroblastoma
Dr. Daniel J. Ma
Radiation Oncology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
 (0.1 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Daniel Ma is a Radiation Oncologist in Rochester, Minnesota. Dr. Ma is rated as a Distinguished provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Laryngeal Cancer, Anaplastic Thyroid Cancer, Thyroid Cancer, and Human Papillomavirus Infection. Dr. Ma is currently accepting new patients.

Experienced in Olfactory Neuroblastoma
Dr. Michelle A. Neben-Wittich
Radiation Oncology | Radiology
Experienced in Olfactory Neuroblastoma
Dr. Michelle A. Neben-Wittich
Radiation Oncology | Radiology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michelle Neben-Wittich is a Radiation Oncologist and a Radiologist in Rochester, Minnesota. Dr. Neben-Wittich is rated as an Advanced provider by MediFind in the treatment of Olfactory Neuroblastoma. Her top areas of expertise are Adenoid Cystic Carcinoma, Familial Pancreatic Cancer, Melanoma of the Eye, and Anal Cancer. Dr. Neben-Wittich is currently accepting new patients.

Experienced in Olfactory Neuroblastoma
Dr. David M. Routman
Radiation Oncology
Experienced in Olfactory Neuroblastoma
Dr. David M. Routman
Radiation Oncology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
 (0.1 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Routman is a Radiation Oncologist in Rochester, Minnesota. Dr. Routman is rated as an Advanced provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Human Papillomavirus Infection, Head and Neck Squamous Cell Carcinoma (HNSCC), Olfactory Neuroblastoma, and Metastatic Brain Tumor. Dr. Routman is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Foote's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 47 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile